ProCE Banner Series

Experts Debate and Discuss Therapeutic Strategies Using CDK4/6 Inhibitors Across Breast Cancer

Join us for this interactive, case-based, CME-certified live symposium at SABCS 2024 to learn the latest expert perspectives on optimizing care with CDK4/6 inhibitors for patients with breast cancer. Be sure to bring your questions for the expert panel.

This symposium is sponsored by Clinical Care Options, LLC and supported by grants from Lilly and Novartis Pharmaceuticals Corporation. This is not an official program of the San Antonio Breast Cancer Symposium®

  AMA
Who Should Attend

This program is intended for physicians and other healthcare professionals who care for patients with breast cancer.

All Events

Experts Debate and Discuss Therapeutic Strategies Using CDK4/6 Inhibitors Across Breast Cancer

Past Events

December

10

2024

7:00 PM - 9:00 PM Central Time (CT)

In-person

Marriott Rivercenter on the River Walk Hotel, 101 Bowie Street, San Antonio, Texas 78205

7:30 PM - 9:00 PM Central Time (CT)

Virtual

Faculty

ProCE Banner Faculty
Jame Abraham, MD, FACP

Enterprise Chair and Professor of Medicine
Department of Hematology and Medical Oncology
Cleveland Clinic
Cleveland, Ohio

ProCE Banner Faculty
William J. Gradishar, MD, FACP

Professor of Medicine
Director of Breast Medical Oncology
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

ProCE Banner Faculty
Laura M. Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Topics

Breast cancers

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge, competence, and confidence of learners to optimally select and sequence therapy with CDK4/6 inhibitors for patients with high-risk HR-positive/HER2-negative breast cancer. 

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with breast cancer. 

Learning Objectives
Upon completion of this event, participants should be able to:

  • Assess the risk of recurrence or progression in patients with HR+/HER2- EBC and MBC and the implications for therapy selection
  • Select adjuvant therapies for patients with high-risk, HR+/HER2- EBC based on tumor characteristics, predictive biomarkers, the latest clinical data, approvals, guidelines, and expert recommendations
  • Apply risk assessment, current evidence, approvals, and guidelines, as well as expert recommendations, to formulate a sequence of treatments for patients with HR+/HER2- MBC
  • Address challenges to adherence to oral therapy with CDK4/6 inhibitors in patients with HR+/HER2- breast cancer

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.